What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment

Polycystic ovary syndrome, the most common gynecological endocrinopathy, is burdened with a state of hyperinsulinemia and insulin resistance in 50–80% of affected women. Wherever the origin of these metabolic abnormalities lies, their pathogenetic role in determining, perpetuating, and worsening the...

Descripción completa

Detalles Bibliográficos
Autores principales: Romualdi, Daniela, Versace, Valeria, Lanzone, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
The Many Faces of PCOS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236839/
https://www.ncbi.nlm.nih.gov/pubmed/32435760
http://dx.doi.org/10.1177/2633494120908709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236839/
https://www.ncbi.nlm.nih.gov/pubmed/32435760
http://dx.doi.org/10.1177/2633494120908709

Ejemplares similares